Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue
Vrinda Gote, Anantha Ram Nookala, Pradeep Kumar Bolla, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 9, pp. 4673-4673
Open Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

Targeting Drug Chemo-Resistance in Cancer Using Natural Products
Wamidh H. Talib, Ahmad R. Alsayed, Muna Barakat, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1353-1353
Open Access | Times Cited: 129
Insights on functionalized carbon nanotubes for cancer theranostics
Lu Tang, Qiaqia Xiao, Yijun Mei, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 115
Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: An update
Vaskuri G. S. Sainaga Jyothi, Raviteja Bulusu, Balaga Venkata Krishna Rao, et al.
International Journal of Pharmaceutics (2022) Vol. 624, pp. 122022-122022
Closed Access | Times Cited: 92
Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer
Reyhaneh Farghadani, Rakesh Naidu
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 4, pp. 2144-2144
Open Access | Times Cited: 77
Nanomedicines and nanomaterials for cancer therapy: Progress, challenge and perspectives
Ziwei Jing, Qiuzheng Du, Xiaojian Zhang, et al.
Chemical Engineering Journal (2022) Vol. 446, pp. 137147-137147
Closed Access | Times Cited: 70
TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy
Desh Deepak Singh, Dharmendra Kumar Yadav
Biomedicines (2021) Vol. 9, Iss. 8, pp. 876-876
Open Access | Times Cited: 64
Classic and New Markers in Diagnostics and Classification of Breast Cancer
Roman Beňačka, Daniela Szabóová, Zuzana Guľašová, et al.
Cancers (2022) Vol. 14, Iss. 21, pp. 5444-5444
Open Access | Times Cited: 57
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity
Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 40
Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
Mangala Hegde, Nikunj Naliyadhara, Jyothsna Unnikrishnan, et al.
Cancer Letters (2023) Vol. 556, pp. 216066-216066
Closed Access | Times Cited: 37
Chitosan-Based Nano-Smart Drug Delivery System in Breast Cancer Therapy
Yedi Herdiana, Nasrul Wathoni, Dolih Gozali, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 879-879
Open Access | Times Cited: 30
The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies
Fan Yang, Qingjie He, Xiangpeng Dai, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 27
Galangin-Loaded Gold Nanoparticles: Molecular Mechanisms of Antiangiogenesis Properties in Breast Cancer
Malik H. Qaddoori, Hanady S. Al‐Shmgani
International Journal of Breast Cancer (2023) Vol. 2023, pp. 1-14
Open Access | Times Cited: 23
A review of FDA approved drugs and their formulations for the treatment of breast cancer
Mohini Chaurasia, Romi Singh, Srija Sur, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 22
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer
Shan Liu, Xingda Zhang, Wenzheng Wang, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 13
Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3′-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer
Rupali Sarkar, Souradeep Biswas, Rituparna Ghosh, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 12
Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic Aspects
Ya-ruo Lei, Xian-lu He, Jun Li, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 2, pp. 52-52
Open Access | Times Cited: 9
A Carrier-Free Ultrasound-Responsive Polyphenol Nanonetworks with Enhanced Sonodynamic-Immunotherapy for Synergistic Therapy of Breast Cancer
Shen‐Zhen Ren, Mingzhe Zhang, Chunxiu Cai, et al.
Biomaterials (2025) Vol. 317, pp. 123109-123109
Closed Access | Times Cited: 1
Application of Nano Drug Delivery System (NDDS) in Cancer Therapy: A Perspective
Junyu Liu, Shuqin Li, Jia Wang, et al.
Recent Patents on Anti-Cancer Drug Discovery (2022) Vol. 18, Iss. 2, pp. 125-132
Closed Access | Times Cited: 36
How docetaxel entrapment, vesicle size, zeta potential and stability change with liposome composition–A formulation screening study
Ann Mari Holsæter, Kristina Wizgird, Iselin Karlsen, et al.
European Journal of Pharmaceutical Sciences (2022) Vol. 177, pp. 106267-106267
Open Access | Times Cited: 33
Novel roles of RNA-binding proteins in drug resistance of breast cancer: from molecular biology to targeting therapeutics
Yinghuan Cen, Letian Chen, Zihao Liu, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 16
Nano-drug delivery system for the treatment of multidrug-resistant breast cancer: Current status and future perspectives
Lanwen Gao, Fansu Meng, Zhenjiang Yang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117327-117327
Open Access | Times Cited: 6
Recent advances in the development of multifunctional lipid-based nanoparticles for co-delivery, combination treatment strategies, and theranostics in breast and lung cancer
Yan Shan Loo, N. Idayu Zahid, Thiagarajan Madheswaran, et al.
Journal of Drug Delivery Science and Technology (2022) Vol. 71, pp. 103300-103300
Closed Access | Times Cited: 24
lncRNA MALAT1 Regulates the Resistance of Breast Cancer Cells to Paclitaxel Via the miR-497-5p/ SHOC2 axis
Chang Shi, Shuangjie Ren, Xiaodong Zhao, et al.
Pharmacogenomics (2022) Vol. 23, Iss. 18, pp. 973-985
Open Access | Times Cited: 24
Synthesis of doxorubicin-loaded peptosomes hybridized with gold nanorod for targeted drug delivery and CT imaging of metastatic breast cancer
Maliheh Hasannia, Khalil Abnous, Seyed Mohammad Taghdisi, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 23
Tumor microenvironment diversity and plasticity in cancer multidrug resistance
Zhi Li, Peihao Yin
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188997-188997
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top